Diverse Bioactive Portfolio CES maintains a portfolio of FDA-cleared proprietary spinal technologies, including the EVOS-ha lumbar interbody system, and has expanded into cervical and SI joint solutions with DLIF variants, signaling cross-sell opportunities across spine clinics and hospitals.

Strategic Partnerships The collaboration with Promimic AB to develop the EVOL SI Sacroiliac Joint Fusion System demonstrates a willingness to co-develop differentiated implants, creating paths for partnerships to accelerate market access.

Value Based Positioning CES positions itself on value for patients, payers, and providers, aligning with demand for clinically and economically efficient implants and enabling sales conversations around ROI and reimbursement.

Channel Growth Opportunities With a lean, privately owned team, CES can scale through distributors, OEM partnerships, and co-marketing arrangements to broaden market reach without a large in-house sales force.

Regulatory Market Readiness A track record of FDA clearances for bioactive technologies and ongoing product introductions position CES to capitalize on spinal market growth as surgeons seek differentiated, next-generation solutions.